There are no generalizable rational treatments for patients with mitochondrial diseases. We propose here to study two new approaches to treat patients with mitochondrial diseases due to mutations in mtDNA. First, we have found that rapamycin (Sirolimus), an FDA-approved drug that induces autophagy, selectively targets mitochondria containing mutated mtDNAs, but not those harboring normal mtDNAs, for autophagic destruction. We will therefore examine the ability of rapamycin to restore mitochondrial function in heteroplasmic cells (""""""""heteroplasmic shifting""""""""), and use biochemical, functional, and microarray-based approaches to determine how mutant mtDNAs and dysfunctional mitochondria are recognized and degraded by the cell's autophagic machinery. Second, we have found that a number of analogs of CoQ and vitamin E developed by Edison Pharmaceuticals can rescue the viability of cells from patients with MELAS (""""""""functional rescue""""""""). We will therefore study Edison compounds in patient cells harboring various pathogenic mtDNA mutations in greater detail, and will also try to determine the mechanism by which these compounds work, using biochemical and genetic approaches. If successful, use of both rapamycin and Edison compounds could be the the basis of the first rational treatments of mtDNA-based OxPhos diseases.
There are no rational treatments for mitochondrial disorders due to mutations in mtDNA. Our finding that rapamycin can target and destroy delsctively mitochondria harboring mutated, but not wild-type, mtDNAs and that new analogs of CoQ and vitamin E developed by Edison Pharmaceuticals can improve viability of heteroplasmic cells harboring mutated mtDNAs, hold out the promise that such treatments may be possible.
|Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312|
|Pera, Marta; Larrea, Delfina; Guardia-Laguarta, Cristina et al. (2017) Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J 36:3356-3371|
|Fryer, Robert H; Bain, Jennifer M; De Vivo, Darryl C (2016) Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options. Pediatr Neurol 56:59-61|
|Varma, Hemant; Faust, Phyllis L; Iglesias, Alejandro D et al. (2016) Whole exome sequencing identifies a homozygous POLG2 missense variant in an infant with fulminant hepatic failure and mitochondrial DNA depletion. Eur J Med Genet 59:540-5|
|Piekutowska-Abramczuk, Dorota; Kocy?a-Karczmarewicz, Beata; Ma?kowska, Maja et al. (2016) No Evidence for Association of SCO2 Heterozygosity with High-Grade Myopia or Other Diseases with Possible Mitochondrial Dysfunction. JIMD Rep 27:63-8|
|Cloonan, Suzanne M; Glass, Kimberly; Laucho-Contreras, Maria E et al. (2016) Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med 22:163-74|
|Engelstad, Kristin; Sklerov, Miriam; Kriger, Joshua et al. (2016) Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy. Hum Reprod 31:1058-65|
|Ripolone, Michela; Ronchi, Dario; Violano, Raffaella et al. (2015) Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy. JAMA Neurol 72:666-75|
|Quinzii, Catarina M; Hirano, Michio; DiMauro, Salvatore (2014) Mutant COQ2 in multiple-system atrophy. N Engl J Med 371:81-2|
|Area-Gomez, Estela; Schon, Eric A (2014) Mitochondrial genetics and disease. J Child Neurol 29:1208-15|
Showing the most recent 10 out of 241 publications